Targeting DNA topoisomerase I with non-camptothecin poisons

Research output: Contribution to journalArticlepeer-review


DNA topoisomerase I is required for DNA relaxation during a variety of cellular functions. The identification of camptothecins as specific enzyme poisons and their clinical efficacy have stimulated extensive efforts to exploit topoisomerase I as a therapeutic target for cancer. However, several limitations of camptothecins, such as low solubility and stability, high toxicity, and the occurrence of resistance, have encouraged the development of non-camptothecin topoisomerase I inhibitors. Different natural and synthetic compounds (e.g., indolocarbazoles, dibenzonaphthyridine and indenoisoquinoline) have been extensively studied as alternatives to camptothecins and have been proved to be promising therapeutic agents. In this review, we comparatively evaluate the preclinical results obtained with the different non-camptothecin poisons proposed thus far as topoisomerase I inhibitors, with special reference to cellular pharmacology, and discuss the perspective for their use in the clinical setting.

Original languageEnglish
Pages (from-to)1238-1257
Number of pages20
JournalCurrent Medicinal Chemistry
Issue number8
Publication statusPublished - Mar 2012


  • Cellular pharmacology
  • Clinical studies
  • Dibenzonaphthyridines
  • DNA topoisomerase I
  • Drug resistance
  • Indenoisoquinolines
  • Indolocarbazoles
  • Lamellarins
  • Topopyrones
  • Tumor cells

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology


Dive into the research topics of 'Targeting DNA topoisomerase I with non-camptothecin poisons'. Together they form a unique fingerprint.

Cite this